McKesson completed the acquisition of Rx Savings Solutions, LLC and SCRI Oncology, LLC during fiscal year 2024. These acquisitions are intended to enhance the company's prescription technology solutions and oncology research capabilities, respectively.

McKesson completed the divestiture of its European businesses in fiscal year 2023, including its Austrian and UK operations. This strategic move was aimed at streamlining operations and focusing on core markets.

McKesson is investing in new and existing distribution centers, technology, and automation to improve efficiency and enhance capabilities. These investments include artificial intelligence and data analytics to support productivity and innovation.

McKesson has approved a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts, including streamlining infrastructure and realizing long-term sustainable growth. These initiatives include employee severance, asset impairments, and accelerated depreciation.

McKesson has recorded a $149 million charge related to estimated liability for opioid-related litigation and claims, and continues to engage in settlement discussions. The company is working to resolve these complex legal issues.

McKesson continues to implement programs to help achieve greater consistency and accuracy both internally and for customers, as well as make investments to access capacity and innovation. They are also focused on improving supply chain management and customer service.

McKesson is subject to various legal disputes, including opioid-related litigation, and is also subject to extensive regulations. These factors could have a material adverse impact on the company's business and financial results.

McKesson acknowledges the risk of cybersecurity incidents, which could compromise technology systems, data, and operations. The company is actively working to mitigate these risks, but such incidents could have a material adverse effect on its business.

Changes in healthcare policies and reimbursement models, including those related to Medicare and Medicaid, could negatively impact McKesson's revenue and profitability. The company is closely monitoring these developments.

McKesson faces intense competition from various national, regional, and local distributors, as well as from pharmaceutical manufacturers and other healthcare providers. This competition could impact pricing power and market share.

McKesson aims to maintain a competitive edge by offering a broad range of services, including technology solutions, and by focusing on quality, innovation, and customer service. This helps them differentiate in a competitive market.

The pharmaceutical distribution industry is experiencing increasing consolidation, which could lead to greater pricing power among competitors and potentially impact McKesson's market position and profitability.

McKesson is implementing various initiatives, including restructuring programs, to streamline operations, reduce costs, and improve overall efficiency. These initiatives include employee severance, asset impairments, and accelerated depreciation.

McKesson is focused on improving its supply chain management to ensure timely and cost-effective delivery of products. This includes optimizing inventory levels and enhancing distribution capabilities.

McKesson is making changes to its cost structure across its various segments, including the U.S. Pharmaceutical, Prescription Technology Solutions, and Medical-Surgical Solutions segments, to improve overall financial performance.

McKesson is investing in technology and automation, including artificial intelligence and data analytics, to enhance its capabilities and improve efficiency. These investments are aimed at supporting productivity and innovation.

McKesson is focused on digital transformation initiatives to improve customer experience and streamline operations. These initiatives include the implementation of new technology platforms and digital tools.

The acquisition of Rx Savings Solutions is intended to enhance McKesson's prescription technology solutions and provide additional value to its customers. This acquisition is part of the company's strategy to innovate and improve its offerings.

McKesson has engaged in share repurchases, including through accelerated share repurchase programs, as a way to return capital to shareholders. The company repurchased $6.6 billion of shares in fiscal year 2024.

McKesson has declared regular quarterly cash dividends and anticipates continuing to pay quarterly dividends in the future. The payment and amount of future dividends will depend on various factors, including financial condition and capital requirements.

McKesson is investing in capital expenditures related to property, plant, and equipment, and capitalized software to support its strategic growth initiatives. These investments are focused on enhancing capabilities and improving efficiency.

McKesson is committed to environmental sustainability and responsible practices, including reducing its carbon footprint and managing its environmental impact. The company is also focused on compliance with environmental regulations.

McKesson is focused on promoting diversity and inclusion in the workforce, with various initiatives aimed at creating a more inclusive and equitable workplace. This includes efforts to increase representation of women and people of color.

McKesson emphasizes ethical conduct and corporate governance, with various policies and procedures in place to ensure compliance and integrity. This includes a code of conduct applicable to all employees and directors.

McKesson operates in a highly regulated industry, and is subject to various federal, state, and local regulations. These regulations could impact the company's operations and financial results.

McKesson's financial performance could be impacted by various macroeconomic conditions, including inflation, economic slowdowns, and fluctuations in interest rates and currency exchange rates. The company is monitoring these conditions.

McKesson's international operations could be affected by geopolitical risks and uncertainties, including political instability and trade disputes. The company is monitoring these risks and taking steps to mitigate their potential impact.